{"denoms":[{"counts":[{"groupId":"BG000","value":"9"}],"units":"Participants"}],"groups":[{"description":"Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.","id":"BG000","title":"HSC835"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.16","value":"59.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety Analysis Set: The Safety analysis included all enrolled patients who were transplanted with HSC835 (any patient with a date for HSC835 transplant)."}